Treatment with nusinersen/spinraza resulted in overall survival and improved life (quality).
But the incremental costs above 21 million SVENSK krona (EUR 2 million) [mainly related to Nusinersen maintenance therapy.
Nusinersen was not cost-effective when using a willingness-to-pay threshold of 2 million SVENSK krona (€195,600)
This was recently considered in a discussion by the Agency for Dentistry and Pharmaceutical Services (TLV)
as an adequate threshold for rare diseases.
Nonetheless, Sweden, approval in 2017 Nusinersen/Spinraza for all patients wirh type I=III under age of 18